Soluble ST2 as a Predictive Biomarker for Acute Graft‐Versus‐Host Disease Post ‐Allogeneic Stem Cell Transplantation
Clinical Transplantation · 2025-03 · 39 (3)
DOI: 10.1111/ctr.70108 ↗At a glance
Journal article in Clinical Transplantation, published online on 2025-03-04. Written by Ken Huang and 7 co-authors. Institution: Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Major MEDLINE topics: Graft vs Host Disease, Interleukin-1 Receptor-Like 1 Protein, Biomarkers, Hematopoietic Stem Cell Transplantation. Cited 4 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Key R&D Program of China, NHC Key Laboratory of Thalassemia Medicine, Guangxi Key laboratory of Thalassemia Research.
Abstract (original language)
Background
Acute graft‐versus‐host disease (aGVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Identifying reliable biomarkers for early prediction of aGVHD could enable timely interventions and improve patient outcomes.
Objective
This study aims to assess whether levels of specific cytokines can serve as predictive markers for the onset and severity of aGVHD.
Methods
Plasma levels of IL‐6, IFN‐γ, TNF‐α, sST2, CD25, and REG3α were measured via ELISA in 50 allo‐HSCT patients (20 with aGVHD and 30 without aGVHD) on Days +7, +14, and +21 post ‐ transplantation. Receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses were used to assess the predictive performance of these biomarkers.
Results
Among the six biomarkers analyzed, sST2 demonstrated the highest predictive accuracy for aGVHD. Elevated sST2 levels at Days +14 and +21 posttransplantation significantly correlated with aGVHD occurrence (AUC = 0.7092 at Day +21) and gastrointestinal aGVHD (AUC = 0.8007 at Day +14). sST2 also showed strong predictive performance for severe aGVHD (Grade II‐IV), with AUC values of 0.8125 at Day +7 and 0.8021 at Day +14. Other biomarkers, including IL‐6, REG3α, CD25, and TNF‐α, exhibited dynamic changes but lacked robust predictive value for aGVHD onset or severity. These findings support sST2 as a promising biomarker for early risk stratification of aGVHD.
Conclusion
SST2 is a promising biomarker for the early prediction of aGVHD, offering potential for guiding proactive therapeutic strategies in allo‐HSCT patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Pediatrics, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
- Guangxi Medical University, Nanning, China.
- Institute of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
ORCID profiles: Mengxin Yang
Funding
- National Key R&D Program of China
- NHC Key Laboratory of Thalassemia Medicine
- Guangxi Key laboratory of Thalassemia Research
- National Key Research and Development Program of China
Cite
APA
Huang, K., Yang, M., Huang, J., Cao, Y., Zhou, Y., Pang, G., Zhao, J., & Luo, J. (2025). Soluble ST2 as a Predictive Biomarker for Acute Graft‐Versus‐Host Disease Post ‐Allogeneic Stem Cell Transplantation. Clinical Transplantation, 39(3). https://doi.org/10.1111/ctr.70108
Vancouver
Huang K, Yang M, Huang J, Cao Y, Zhou Y, Pang G, et al. Soluble ST2 as a Predictive Biomarker for Acute Graft‐Versus‐Host Disease Post ‐Allogeneic Stem Cell Transplantation. Clinical Transplantation. 2025;39(3). doi:10.1111/ctr.70108
BibTeX
@article{Huang2025,
author = {Huang, Ken and Yang, Mengxin and Huang, Jinfang and Cao, Yaxuan and Zhou, Yuhang and Pang, Guanxiu and Zhao, Jie and Luo, Jianming},
title = {Soluble ST2 as a Predictive Biomarker for Acute Graft‐Versus‐Host Disease Post ‐Allogeneic Stem Cell Transplantation},
journal = {Clinical Transplantation},
year = {2025},
volume = {39},
number = {3},
doi = {10.1111/ctr.70108}
}
EUVIMED